Small-Firm Strategic Research Partnerships: The Case of Biotechnology

This paper provides an overview of the theoretical motivation and the empirical literature on small firm strategic alliances in biotechnology, an industry where these alliances have proliferated. We begin by examining the alliance strategy for knowledge-based small firms in general and then turn our attention to the case of biotech.

[1]  Albert N. Link,et al.  Firm size, university based research, and the returns to R&D , 1990, Small Business Economics.

[2]  B. Kogut.  Joint ventures: Theoretical and empirical perspectives , 1988 .

[3]  George A. Akerlof.  The Market for “Lemons”: Quality Uncertainty and the Market Mechanism , 1970 .

[4]  David B. Audretsch,et al.  Innovation and Technological Change: An International Comparison , 1991 .

[5]  H. H. Newman.  Strategic Groups and the Structure-Performance Relationship , 1978 .

[6]  Steven M. Fazzari,et al.  Financing Constraints and Corporate Investment , 1987 .

[7]  G. Pisano.  The R&D Boundaries of the Firm: An Empirical Analysis , 1990 .

[8]  M. Sharp,et al.  The science of nations: European multinationals and American biotechnology , 1999 .

[9]  Richard R. Nelson,et al.  The sources of economic growth , 1996 .

[10]  John Patrick Swann.  The emergence of cooperative research between American universities and the pharmaceutical industry, 1920-1940 , 1988 .

[11]  Paula E. Stephan,et al.  The Changing Rewards to Science , 1998 .

[12]  Stephen Hill,et al.  The theory of the growth of the firm , 1981 .

[13]  I. Cockburn,et al.  Absorptive Capacity, Coauthoring Behavior, and the Organization of Research in Drug Discovery , 2003 .

[14]  J. Tirole,et al.  The Management of Innovation , 1994 .

[15]  E. Penrose.  The theory of the growth of the firm twenty-five years after , 1960 .

[16]  Sanford J. Grossman,et al.  The Costs and Benefits of Ownership: A Theory of Vertical and Lateral Integration , 1986 .

[18]  O. Hart,et al.  Incomplete Contracts and Renegotiation , 1988 .

[19]  G. Pisano.  The governance of innovation: Vertical integration and collaborative arrangements in the biotechnology industry☆ , 1991 .

[20]  Nicholas Kalaitzandonakes,et al.  Vertical and Horizontal Coordination in the Agro-biotechnology Industry: Evidence and Implications , 1997, Journal of Agricultural and Applied Economics.

[21]  Benjamin Gomes-Casseres.  Group versus group: How alliance networks compete , 1994 .

[22]  Alfred Kleinknecht,et al.  Measuring R&D in Small Firms: How Much Are We Missing? , 1987 .

[23]  Maryann P. Feldman,et al.  Closing the innovative loop: moving from the laboratory to the shop floor in biotechnology manufacturing , 2001 .

[24]  F. Scherer,et al.  Using Linked Patent and R&D Data to Measure Interindustry Technology Flows , 1984 .

[25]  L. Zucker,et al.  Intellectual Capital and the Firm: The Technology of Geographically Localized Knowledge Spillovers , 1994 .

[26]  Raghuram G. Rajan,et al.  The Benefits of Firm-Creditor Relationships: Evidence from small business data. * , 1993 .

[27]  J. Stiglitz,et al.  Credit Rationing in Markets with Imperfect Information , 1981 .

[28]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[29]  Alfred Kleinknecht,et al.  Firm size and innovation , 1991 .

[30]  Paula E. Stephan,et al.  The Changing Rewards to Science: The Case of Biotechnology , 1998 .

[31]  Toby E. Stuart,et al.  Interorganizational Endorsements and the Performance of Entrepreneurial Ventures , 1999 .

[32]  John Bessant,et al.  Company and campus partnership , 1993 .

[33]  Louis Galambos,et al.  Pharmaceutical Firms and the Transition to Biotechnology: A Study in Strategic Innovation , 1998, Business History Review.

[34]  R. Merges,et al.  The Control of Technology Alliances: An Empirical Analysis of the Biotechnology Industry , 2003 .

[35]  Mark D. Dibner,et al.  Patterns of Strategic Choice in Emerging Firms: Positioning for Innovation in Biotechnology , 1990 .

[36]  Gary P. Pisano,et al.  The Development Factory: Unlocking the Potential of Process Innovation , 1996 .

[37]  David L. Deeds,et al.  An Analysis of the Critical Role of Public Science in Innovation: The Case of Biotechnology , 2000 .

[38]  Josh Lerner,et al.  Do Equity Financing Cycles Matter? Evidence from Biotechnology Alliances. NBER Working Paper No. 7464 , 2003 .

[39]  Thorsten Posselt.  The alliance revolution — The new shape of business rivalry , 1998 .

[40]  Oliver Hart,et al.  Firms, contracts, and financial structure , 1995 .

[41]  Michael Useem,et al.  The Alliance Revolution: The New Shape of Business Rivalry@@@Investor Capitalism: How Money Managers are Changing the Face of Corporate America , 1996 .

[42]  Stephen Roper.  Under-Reporting of R&D in Small Firms: The Impact on International R&D Comparisons , 1999 .

[43]  Paula E. Stephan,et al.  Company-Scientist Locational Links: The Case of Biotechnology , 1996 .

[44]  J. Hagedoorn.  Understanding the rationale of strategic technology partnering: Nterorganizational modes of cooperation and sectoral differences , 1993 .

[45]  Martha Prevezer,et al.  The degree of integration in strategic alliances in biotechnology , 1996 .

[46]  M. Brewer,et al.  Intellectual Capital and the Birth of U.S. Biotechnology Enterprises , 1994 .

[47]  Douglas W. Diamond.  Monitoring and Reputation: The Choice between Bank Loans and Directly Placed Debt , 1991, Journal of Political Economy.

[48]  W. Powell,et al.  Interorganizational Collaboration and the Locus of Innovation: Networks of Learning in Biotechnology. , 1996 .

[49]  R. Zeckhauser.  The challenge of contracting for technological information. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[50]  T. Dublin,et al.  Research policy , 2021, The Routledge Handbook of Gender and EU Politics.

[51]  Louis Galambos,et al.  Networks of Innovation: Vaccine Development at Merck, Sharp and Dohme, and Mulford, 1895-1995 , 1995 .

[52]  R. Caves.  Industrial Organization and New Findings on the Turnover and Mobility of Firms , 1998 .

[53]  Paul Y. Mang,et al.  Exploiting innovation options: an empirical analysis of R& D-intensive firms , 1998 .

[54]  Josh Lerner,et al.  Do Equity Financing Cycles Matter?: Evidence from Biotechnology Alliances , 1999 .

[55]  Thomas Russell,et al.  Imperfect Information, Uncertainty, and Credit Rationing , 1976 .

[56]  Noel P. Greis,et al.  External partnering as a response to innovation barriers and global competition in biotechnology , 1995 .

[57]  David B. Audretsch,et al.  Innovation and Technological Change , 2003 .

[58]  M. Porter,et al.  Market Structure, Oligopoly, and Stability of Market Shares , 1978 .

[59]  Robert F. Service.  Chemical Industry Rushes Toward Greener Pastures , 1998, Science.

[60]  Benjamin Gomes-Casseres.  Alliance Strategies of Small Firms , 1997 .

[61]  D. Jane Bower,et al.  Global R&D networks: The Case Of The Pharmaceutical Industry , 1993 .

[62]  W. Bernard Carlson,et al.  Networks of Innovation: Vaccine Development at Merck, Sharp & Dohme, and Mulford, 1895-1995 , 1999 .